Secondary ALK negative anaplastic large cell lymphoma in a patient with lymphomatoid papulosis of 40 years duration

Márta Marschalkó, Nóra Eros, Péter Holló, Judit Hársing, Gyula Bottlik, Árpád Bátai, Zoltán Csukly, T. Masszi, Zoltán Szentirmai, J. Fodor, S. Kárpáti, A. Matolcsy, Judit Csomor

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A 49 year-old man presented to our clinic. He had a history of lymphomatoid papulosis since childhood. At age 44, regional lymph node manifestation of anaplastic lymphoma kinase (ALK) anaplastic large cell lymphoma (ALCL) developed. Chemotherapy resulted in complete remission of the lymphadenopathy. Four years later, systemic relapse was detected which was refractory to therapy. Histology and immunohistochemistry showed congruent characteristics of multiple skin and lymph node biopsies: diffuse mixed infiltrate with large, anaplastic CD30 cells. Immunophenotype and microscopic morphology suggested a common origin of the different manifestations-however, this could not be proven due to lack of T-cell receptor (TCR) gamma gene rearrangement in most of the samples. The diagnosis of ALK-negative systemic ALCL with cutaneous symptoms was set up at the second flare up, however, the possibility of primary cutaneous ALCL was not excluded steadily. Lymphomatoid papulosis, primary cutaneous ALCL, and systemic ALK ALCL are 3 different entities but the separation of them cannot be solved without distinctive diagnostic tools.

Original languageEnglish
Pages (from-to)708-712
Number of pages5
JournalAmerican Journal of Dermatopathology
Volume32
Issue number7
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Lymphomatoid Papulosis
Anaplastic Large-Cell Lymphoma
Primary Cutaneous Anaplastic Large Cell Lymphoma
Lymph Nodes
T-Cell Receptor gamma Genes
Skin
Gene Rearrangement
Histology
Immunohistochemistry
Biopsy
Recurrence
Drug Therapy
anaplastic lymphoma kinase
Therapeutics

Keywords

  • ALK-negative
  • lymphomatoid papulosis
  • primary cutaneous anaplastic large cell lymphoma
  • systemic anaplastic large cell lymphoma
  • World Health Organization classification

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Dermatology

Cite this

Secondary ALK negative anaplastic large cell lymphoma in a patient with lymphomatoid papulosis of 40 years duration. / Marschalkó, Márta; Eros, Nóra; Holló, Péter; Hársing, Judit; Bottlik, Gyula; Bátai, Árpád; Csukly, Zoltán; Masszi, T.; Szentirmai, Zoltán; Fodor, J.; Kárpáti, S.; Matolcsy, A.; Csomor, Judit.

In: American Journal of Dermatopathology, Vol. 32, No. 7, 10.2010, p. 708-712.

Research output: Contribution to journalArticle

Marschalkó, Márta ; Eros, Nóra ; Holló, Péter ; Hársing, Judit ; Bottlik, Gyula ; Bátai, Árpád ; Csukly, Zoltán ; Masszi, T. ; Szentirmai, Zoltán ; Fodor, J. ; Kárpáti, S. ; Matolcsy, A. ; Csomor, Judit. / Secondary ALK negative anaplastic large cell lymphoma in a patient with lymphomatoid papulosis of 40 years duration. In: American Journal of Dermatopathology. 2010 ; Vol. 32, No. 7. pp. 708-712.
@article{f8250d8a33604d6ba35b2d505409b02d,
title = "Secondary ALK negative anaplastic large cell lymphoma in a patient with lymphomatoid papulosis of 40 years duration",
abstract = "A 49 year-old man presented to our clinic. He had a history of lymphomatoid papulosis since childhood. At age 44, regional lymph node manifestation of anaplastic lymphoma kinase (ALK) anaplastic large cell lymphoma (ALCL) developed. Chemotherapy resulted in complete remission of the lymphadenopathy. Four years later, systemic relapse was detected which was refractory to therapy. Histology and immunohistochemistry showed congruent characteristics of multiple skin and lymph node biopsies: diffuse mixed infiltrate with large, anaplastic CD30 cells. Immunophenotype and microscopic morphology suggested a common origin of the different manifestations-however, this could not be proven due to lack of T-cell receptor (TCR) gamma gene rearrangement in most of the samples. The diagnosis of ALK-negative systemic ALCL with cutaneous symptoms was set up at the second flare up, however, the possibility of primary cutaneous ALCL was not excluded steadily. Lymphomatoid papulosis, primary cutaneous ALCL, and systemic ALK ALCL are 3 different entities but the separation of them cannot be solved without distinctive diagnostic tools.",
keywords = "ALK-negative, lymphomatoid papulosis, primary cutaneous anaplastic large cell lymphoma, systemic anaplastic large cell lymphoma, World Health Organization classification",
author = "M{\'a}rta Marschalk{\'o} and N{\'o}ra Eros and P{\'e}ter Holl{\'o} and Judit H{\'a}rsing and Gyula Bottlik and {\'A}rp{\'a}d B{\'a}tai and Zolt{\'a}n Csukly and T. Masszi and Zolt{\'a}n Szentirmai and J. Fodor and S. K{\'a}rp{\'a}ti and A. Matolcsy and Judit Csomor",
year = "2010",
month = "10",
doi = "10.1097/DAD.0b013e3181d46eba",
language = "English",
volume = "32",
pages = "708--712",
journal = "American Journal of Dermatopathology",
issn = "0193-1091",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Secondary ALK negative anaplastic large cell lymphoma in a patient with lymphomatoid papulosis of 40 years duration

AU - Marschalkó, Márta

AU - Eros, Nóra

AU - Holló, Péter

AU - Hársing, Judit

AU - Bottlik, Gyula

AU - Bátai, Árpád

AU - Csukly, Zoltán

AU - Masszi, T.

AU - Szentirmai, Zoltán

AU - Fodor, J.

AU - Kárpáti, S.

AU - Matolcsy, A.

AU - Csomor, Judit

PY - 2010/10

Y1 - 2010/10

N2 - A 49 year-old man presented to our clinic. He had a history of lymphomatoid papulosis since childhood. At age 44, regional lymph node manifestation of anaplastic lymphoma kinase (ALK) anaplastic large cell lymphoma (ALCL) developed. Chemotherapy resulted in complete remission of the lymphadenopathy. Four years later, systemic relapse was detected which was refractory to therapy. Histology and immunohistochemistry showed congruent characteristics of multiple skin and lymph node biopsies: diffuse mixed infiltrate with large, anaplastic CD30 cells. Immunophenotype and microscopic morphology suggested a common origin of the different manifestations-however, this could not be proven due to lack of T-cell receptor (TCR) gamma gene rearrangement in most of the samples. The diagnosis of ALK-negative systemic ALCL with cutaneous symptoms was set up at the second flare up, however, the possibility of primary cutaneous ALCL was not excluded steadily. Lymphomatoid papulosis, primary cutaneous ALCL, and systemic ALK ALCL are 3 different entities but the separation of them cannot be solved without distinctive diagnostic tools.

AB - A 49 year-old man presented to our clinic. He had a history of lymphomatoid papulosis since childhood. At age 44, regional lymph node manifestation of anaplastic lymphoma kinase (ALK) anaplastic large cell lymphoma (ALCL) developed. Chemotherapy resulted in complete remission of the lymphadenopathy. Four years later, systemic relapse was detected which was refractory to therapy. Histology and immunohistochemistry showed congruent characteristics of multiple skin and lymph node biopsies: diffuse mixed infiltrate with large, anaplastic CD30 cells. Immunophenotype and microscopic morphology suggested a common origin of the different manifestations-however, this could not be proven due to lack of T-cell receptor (TCR) gamma gene rearrangement in most of the samples. The diagnosis of ALK-negative systemic ALCL with cutaneous symptoms was set up at the second flare up, however, the possibility of primary cutaneous ALCL was not excluded steadily. Lymphomatoid papulosis, primary cutaneous ALCL, and systemic ALK ALCL are 3 different entities but the separation of them cannot be solved without distinctive diagnostic tools.

KW - ALK-negative

KW - lymphomatoid papulosis

KW - primary cutaneous anaplastic large cell lymphoma

KW - systemic anaplastic large cell lymphoma

KW - World Health Organization classification

UR - http://www.scopus.com/inward/record.url?scp=77957356475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957356475&partnerID=8YFLogxK

U2 - 10.1097/DAD.0b013e3181d46eba

DO - 10.1097/DAD.0b013e3181d46eba

M3 - Article

VL - 32

SP - 708

EP - 712

JO - American Journal of Dermatopathology

JF - American Journal of Dermatopathology

SN - 0193-1091

IS - 7

ER -